» Articles » PMID: 27588731

Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry

Overview
Journal Clin Cardiol
Date 2016 Sep 3
PMID 27588731
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although the rate of in-hospital ischemic events after myocardial infarction (MI) has dramatically decreased, long-term residual risk may remain substantial. However, most of the information on current residual risk is derived from highly selected randomized trials.

Hypothesis: In patients with previous MI and no prior ischemic stroke/transient ischemic attack (TIA), residual ischemic risk increases over time.

Methods: Using the international Reduction of Atherothrombosis for Continued Health (REACH) registry, we analyzed baseline characteristics and 4-year follow-up of patients with previous MI and no history of stroke/TIA to describe annual rates of recurrent ischemic events globally and by geography. The primary outcome was the composite of cardiovascular death, MI, or stroke. Multivariate analysis identified risk factors associated with recurrent ischemic events.

Results: Data from 16 770 patients enrolled at 5587 sites in 44 countries were analyzed. The rate of the primary outcome increased annually from 4.7% during year 1 to reach a 4-year rate of 15.1%. Compared with North America, Japan experienced lower ischemic event rates (P < 0.01), whereas Eastern Europe (P < 0.01) and the Middle East (P = 0.01) experienced higher ischemic event rates. The presence of congestive heart failure, polyvascular disease, diabetes, atrial fibrillation or flutter, and older age were associated with increased residual risk (all P < 0.01). Statin use was associated with lower ischemic risk (P < 0.01).

Conclusions: In this study, residual ischemic risk after MI accrued progressively up to 4 years of follow-up, emphasizing the value of intensive secondary prevention strategies to minimize residual risk.

Citing Articles

The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis.

Yao Y, Qiu Q, Wang Z, Xu S, Lv Q Am J Cardiovasc Drugs. 2025; .

PMID: 39813003 DOI: 10.1007/s40256-024-00719-4.


.

El Ayech Boudiche F, Boudiche S, Othmani S, Mehri H, Larbi M, Yaakoub A Tunis Med. 2024; 102(3):151-156.

PMID: 38545710 PMC: 11358825. DOI: 10.62438/tunismed.v102i3.4713.


Prognostic Importance of Fractional Flow Reserve and Left Ventricular Systolic Dysfunction After Percutaneous Coronary Intervention.

Sykes R, Hanna R, Berry C JACC Asia. 2024; 4(3):241-243.

PMID: 38463675 PMC: 10920047. DOI: 10.1016/j.jacasi.2023.12.002.


De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis.

Gorog D, Ferreiro J, Ahrens I, Ako J, Geisler T, Halvorsen S Nat Rev Cardiol. 2023; 20(12):830-844.

PMID: 37474795 DOI: 10.1038/s41569-023-00901-2.


Safety and Effectiveness of Evolocumab During Acute and Sub-acute Phases of Acute Coronary Syndrome (ACS): A Systematic Review and Meta-analysis.

Alzarroug A, Al Gahtani H, Algahtani S, Alghamdi H, Alhinti M, Almutairi K Cureus. 2023; 15(2):e35514.

PMID: 37007377 PMC: 10051038. DOI: 10.7759/cureus.35514.


References
1.
Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View

2.
Ducrocq G, Amarenco P, Labreuche J, Alberts M, Mas J, Ohman E . A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation. 2013; 127(6):730-8. DOI: 10.1161/CIRCULATIONAHA.112.141572. View

3.
Smith Jr S, Benjamin E, Bonow R, Braun L, Creager M, Franklin B . AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by.... J Am Coll Cardiol. 2011; 58(23):2432-46. DOI: 10.1016/j.jacc.2011.10.824. View

4.
Puymirat E, Simon T, Steg P, Schiele F, Gueret P, Blanchard D . Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012; 308(10):998-1006. DOI: 10.1001/2012.jama.11348. View

5.
Cannon C, Blazing M, Giugliano R, McCagg A, White J, Theroux P . Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25):2387-97. DOI: 10.1056/NEJMoa1410489. View